Christopher  DelOrefice net worth and biography

Christopher DelOrefice Biography and Net Worth

Christopher DelOrefice serves as executive vice president and chief financial officer for BD (Becton, Dickinson and Company), a leading, global medical technology company based in Franklin Lakes, New Jersey.

DelOrefice joined BD from Johnson & Johnson (J&J), where he served as vice president of Investor Relations. In nearly two decades at J&J, DelOrefice has also held a variety of senior finance leadership roles, including CFO of both the Consumer and Medical Devices segments for North America. He also held finance leadership roles for J&J Supply Chain, Corporate Mergers and Acquisitions, Consumer Global R&D and the Pharmaceutical North America Business Development and Commercial Contracting Finance groups. Prior to J&J, DelOrefice held leadership positions in cost accounting, global audit and financial reporting at Astra Zeneca Pharmaceuticals, AET Films, Inc. and Ametek, Inc.

DelOrefice earned his Bachelor of Science and Master of Business Administration degrees from Villanova University. He received his certified public accountant certification from the Commonwealth of Pennsylvania. He is a member of the Global Investor Relations Executive Council and also remains actively engaged in education and development initiatives at Villanova University.

How old is Christopher DelOrefice?

Mr. DelOrefice is currently 52 years old. There are 7 older executives and no younger executives at Becton, Dickinson and Company. The oldest executive at Becton, Dickinson and Company is Mr. David B. Hickey, Executive VP & President of Life Sciences Segment, who is 60 years old. Learn More on Christopher DelOrefice's age.

How do I contact Christopher DelOrefice?

The corporate mailing address for Mr. DelOrefice and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at [email protected]. Learn More on Christopher DelOrefice's contact information.

Has Christopher DelOrefice been buying or selling shares of Becton, Dickinson and Company?

Christopher DelOrefice has not been actively trading shares of Becton, Dickinson and Company in the last ninety days. Learn More on Christopher DelOrefice's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, insiders at the medical instruments supplier sold shares 6 times. They sold a total of 8,019 shares worth more than $2,132,768.00. The most recent insider tranaction occured on March, 14th when SVP Thomas J Spoerel sold 282 shares worth more than $67,197.78. Insiders at Becton, Dickinson and Company own 0.3% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 3/14/2024.

Christopher DelOrefice Insider Trading History at Becton, Dickinson and Company

See Full Table

Christopher DelOrefice Buying and Selling Activity at Becton, Dickinson and Company

This chart shows Mr. Christopher DelOrefice's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $247.45
Low: $245.33
High: $248.42

50 Day Range

MA: $239.20
Low: $233.57
High: $246.53

2 Week Range

Now: $247.45
Low: $229.85
High: $287.32

Volume

1,093,920 shs

Average Volume

1,475,061 shs

Market Capitalization

$71.49 billion

P/E Ratio

58.64

Dividend Yield

1.57%

Beta

0.42